Rheumatic Disease Center — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$154,240	16
2024	Research	$152,364	8
2023	Research	$183,854	13
2022	Research	$62,628	16
2021	Research	$78,692	20
2020	Research	$88,089	17
2019	Research	$119,045	19

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $321,082 10 payments
Eli Lilly and Company $154,135 28 payments
GlaxoSmithKline, LLC. $135,506 16 payments
AbbVie, Inc. $111,848 38 payments
AstraZeneca UK Limited $58,789 9 payments
Horizon Therapeutics plc $36,499 4 payments
Novartis Pharmaceuticals Corporation $19,602 2 payments
Ucb SA $1,450 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 4, Multicenter, Prospective, Open-Label Study Describing the E $113,173 13 payments
Phase III PsA #2 - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naive to Biologic Disease Modifying Anti-rhe $105,643 2 payments
Phase III PsA #2 (Wk52 driving submission) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naive to Biologic $90,767 1 payment
M15-998 $58,333 16 payments
The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus $54,132 8 payments
AMPLIFIED Study - A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope $50,062 2 payments
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment $41,505 1 payment
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $40,890 6 payments
A Randomized, Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $39,913 5 payments
Taltz Psa Observational Study $35,612 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.